Hypertension, Coronary artery disease, Heart failure, Chronic kidney disease, Atrial fibrillation, High risk vascular disease, Cerebrovascular accident, Diabetes mellitus, High normal blood pressure, Pre-hypertension
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: We will include only English full-articles. The other article including non-English article, short article, and conference abstract will be excluded. We will include parallel-group individual RCTs but not cluster RCTs, or cross-over RCTs. A trial with three or more arms will be accepted. Along with superiority trials, non-inferiority trials will be allowed. Any phase RCT may be included. Trials not reporting data about safety outcomes will be excluded. Key inclusion criteria are as follows. (1) RCTs including RAS-acting agents and control treatment in adult patients. Controls will be classified as placebo or non-placebo. Non-placebo drugs will be defined as any RAS-acting agents. (2) The study with multiple arms where RAS-acting agent is included at least one arm. (3) The study illustrates the safety outcome of cancer.
Exclusion criteria
Exclusion criteria: (1) Systematic review or meta-analysis articles. (2) Retrospective analysis. (3) Single prospective cohort study without a control group. (4) Non-RCT. (5) The republished research literature is excluded unless the research includes new findings related to cancers listed in inclusion criteria. (6) Studies with no or insufficient safety outcomes at the time of the literature search. Two investigators independently will screen all titles, abstracts, and full texts for eligibility. Final inclusion will be decided after resolving discrepancies between the two investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The odds ratio (OR) of cancer with ARNI will be calculated. Network meta-analysis will be performed to compare the incidence of cancer between ARNI and control treatment. We will use five comparison categories: placebo, ARNI, angiotensin-converting-enzyme inhibitors (ACEi), angiotensin-receptor blockers (ARBs), ACEi and ARBs. | — |
Secondary
| Measure | Time frame |
|---|---|
| The odds ratio (OR) of cancer with ACEi, ARBs, ACEi and ARBs will be calculated. The main analysis will be compared individual drug classes with placebo, which will be used as reference. | — |
Countries
Japan
Contacts
Public ContactShintaro Minegishi
Yokohama City University Graduate School of Medicine Department of Cardiology
Outcome results
None listed